Study guide

Immunophenotyping, molecular pathology and tumour genetics

European Board of Ophthalmology Diploma EBOD

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: EBOD Examination, Applications and Regulations

EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals

2 Chapter 2: Physical Optics, Photometry and Lenses

Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid

3 Chapter 3: Instrument Optics, Aberrations and Laser Physics

Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT

4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing

Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses

5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation

Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics

6 Chapter 6: Extraocular Anatomy and Motor Physiology

Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys

7 Chapter 7: Binocular Vision and Amblyopia

Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment

8 Chapter 8: Childhood Assessment and Strabismus Testing

Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts

9 Chapter 9: Esotropia, Exotropia and Vertical Deviations

Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew

10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery

Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles

11 Chapter 11: ROP and Paediatric Ocular Disease

Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding

12 Chapter 12: Ocular Surface Anatomy and Infection

Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis

13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation

Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis

14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies

Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies

15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure

Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency

16 Chapter 16: Surface Reconstruction and Keratoplasty

Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems

17 Chapter 17: Lens Development, Cataract Assessment and Biometry

Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry

18 Chapter 18: IOL Planning and Phacoemulsification

Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques

19 Chapter 19: Cataract Anaesthesia and Surgical Complications

Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO

20 Chapter 20: Corneal and Intraocular Refractive Surgery

Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange

21 Chapter 21: Presbyopia Procedures and Surface Therapeutics

Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin

22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy

Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation

23 Chapter 23: Angle, Disc and Visual-Field Assessment

Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry

24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms

Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure

25 Chapter 25: POAG, Angle Closure and Pigmentary Disease

POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma

26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment

Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers

27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion

Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions

28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy

Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis

29 Chapter 29: Inherited Retina and Electrophysiology

Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina

30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid

AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum

31 Chapter 31: Retinal Breaks and Detachment Repair

PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling

32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma

Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment

33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation

SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation

34 Chapter 34: Infectious Uveitis and Endophthalmitis

Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment

35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy

Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison

36 Chapter 36: Papilloedema, IIH and Afferent Localisation

Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization

37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology

Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies

38 Chapter 38: Central Motor Control and Cranial Nerve Palsies

Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus

39 Chapter 39: Myasthenia and Ocular Myopathy

Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome

40 Chapter 40: Pupillary Pathways and Anisocoria

Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials

41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment

Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation

42 Chapter 42: Lid Repair and Lacrimal Drainage

Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR

43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours

Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma

44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease

Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling

45 Chapter 45: Ocular Trauma and Vascular Systemic Disease

Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease

46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology

Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects

47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations

Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal

Immunophenotyping, molecular pathology and tumour genetics

Key Takeaways Explain This Topic AI

IHC, flow cytometry and molecular assays answer complementary questions and require clinical–morphological correlation.

Scant or degraded vitreous material can make a negative lymphoma test inconclusive.

Somatic tumour variants and germline inherited variants have different implications.

HLA-A*02:01 is a specific tebentafusp eligibility requirement, while prognostic testing estimates metastatic risk.

Last updated: October 2026

A marker is evidence, not a diagnosis by itself

Immunohistochemistry (IHC) uses antibodies to identify antigens in tissue. Flow cytometry characterizes antigen expression in suspended cells. Molecular tests identify genetic or other nucleic-acid changes. Each addresses a different question, and the final diagnosis integrates morphology, phenotype, molecular findings and the clinical presentation. A single positive marker should not override an incompatible tissue pattern.

Review the suspected lineage before choosing a panel. Cytokeratins support epithelial differentiation, melanocytic markers support a melanocytic phenotype, and lymphoid markers help classify lymphoid populations. These are not perfectly exclusive labels. Controls, staining location, intensity and the distribution among cells affect interpretation. Small samples and prior treatment can limit the result.

Lymphoid assessment

Lymphoma evaluation distinguishes reactive lymphoid tissue from a clonal malignant process and then identifies the subtype. B-cell and T-cell markers, light-chain patterns and proliferation markers may be combined with architecture and molecular studies. Flow cytometry can detect abnormal populations when enough viable cells are available, but a negative result from a scant or degraded sample does not exclude lymphoma.

For suspected vitreoretinal lymphoma, coordinate acquisition and rapid transport with pathology. Cytology, immunophenotyping, molecular tests and cytokine analysis can be complementary. An IL-10 predominance may support the diagnosis in context, but inflammation and sampling limitations prevent treating a ratio as a universal standalone rule. A MYD88 variant can support selected B-cell lymphoma diagnoses but does not replace interpretation of the specimen and systemic context.

Recent corticosteroids may reduce cell yield or alter appearances. When clinically safe, the diagnostic plan should account for this, but do not impose an arbitrary drug-free interval on every urgent patient. Repeat or alternative sampling may be needed after a nondiagnostic result. Evaluate central nervous system involvement through the relevant team rather than assuming an ocular-only disease.

DNA, RNA and cytogenetic methods

Polymerase chain reaction (PCR) amplifies a targeted nucleic-acid sequence. It can assist pathogen detection, clonality or selected variant analysis. A positive pathogen signal may represent contamination or a finding requiring clinical correlation; a negative test can reflect timing, low organism load or an inadequate sample. Test selection should follow the suspected disease and the laboratory's validated assay.

Fluorescence in situ hybridization (FISH) examines specified chromosomal targets. Sequencing can examine individual genes or wider panels, while expression profiling characterizes transcript patterns. These techniques differ in resolution and purpose. A negative targeted test does not exclude a genetic change outside the region assessed. Explain the test's limits when giving a patient or family a result.

  • Technique Main question Limitation
  • IHC Tissue antigen phenotype Marker overlap and technical artifacts
  • Flow cytometry Cellular populations and aberrant phenotype Needs appropriate cells and transport
  • PCR Selected pathogen, clonality or variant Targeted assay and sampling dependence
  • FISH Specified chromosomal alteration Does not survey every possible variant
  • Sequencing Genetic variants in examined regions Coverage and interpretation limits
  • Expression profile Prognostic or biological pattern Assay- and tumour-specific validation
  • Uveal melanoma and prognostic testing

Uveal melanoma biology differs from cutaneous melanoma. Chromosomal and molecular features, including chromosome 3 status and alterations involving BAP1, SF3B1 or EIF1AX, can inform prognosis in the appropriate setting. An expression class or molecular marker estimates risk; it is not a certainty that an individual will or will not develop metastasis. Sampling heterogeneity and technical adequacy also matter.

Differentiate somatic tumour testing from germline testing . A BAP1 alteration in a tumour does not automatically prove an inherited syndrome. Young onset, multiple relevant tumours or family history may prompt genetic counselling and a germline pathway. Consent should cover implications for relatives, uncertainty and how results may affect surveillance.

HLA typing has a treatment-selection role for tebentafusp: its European indication requires HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma. That eligibility marker is different from a general prognostic test. Treatment can cause cytokine release syndrome and requires oncology supervision and an appropriate monitoring setting.

Clinical application

A vitreous sample with few damaged cells and negative flow cytometry is inconclusive if clinical suspicion remains high. A tumour expression result indicating high risk calls for informed surveillance discussion, not a deterministic prediction of survival. A tumour-only genetic variant should not be described as inherited without germline evaluation. State what the test measures, whether the specimen was adequate and what decision the result changes.

Sources: RCPath ophthalmic reporting recommendations , RCPath lymphoma reporting and EMA Kimmtrak .

Sections you finish are checked off in the contents.

  • Up Next
  • Uveal melanoma and retinoblastoma
  • Continue learning